Emris Pharma
Preventing EGFRi skin toxicities, enhancing patient quality of life & Compliance for Cancer Patients
StartupEmris Pharma is a Nazareth-based startup in the Health Tech & Life Sciences sector, established in 2023. Preventing EGFRi skin toxicities, enhancing patient quality of life & Compliance for Cancer Patients. Emris Pharma was founded by Lyora Aharonov. Key investors include NGT HealthCare II, Israel Innovation Authority. The company has 1-10 employees. Core technologies: Biologicals, Molecules.
The company follows a B2B business model. Product stage: R&D. The company holds 1 patent.
- StagePre-Seed
- ProductR&D
- ModelB2B
- Employees1-10
- HQNazareth
- Last RoundUndisclosed
- NGT HealthCare IILead
- Israel Innovation Authority
Lyora AharonovCo-founder & CEO
2 articles covered by sources including www.calcalistech.com,
www.prnewswire.com.
What does Emris Pharma do?
EMRIS Pharma is developing a novel small molecule topically administrated for the prevention of skin toxicities induced by EGFR inhibitors (EGFRi). This innovative therapy intends to improve cancer patients’ quality of life and compliance with cancer therapy. Current treatment strategies and new developments focus on symptom reduction post-EGFR inhibition when our solution blocks the initial trigger causing skin toxicity, the drug-receptor interaction. The company new approach will prevent skin toxicity, enabling more cancer patients to go about their daily lives without compromising their anticancer treatment. Its solution (SDT 011) is targeting a huge market with global unmet need. The market is also expected to substantially grow due to new combinations of cancer treatments with EGFRi and a potential product approval of new EGFRi bi-specific antibodies. SDT 011 (EMR-001) is the first-to-market product in the pipeline of the company. Additional new candidate compounds are currently in development for Tyrosine Kinase Inhibitors’ induced skin toxicities that can substantially contribute to the market size.
Who founded Emris Pharma?
Emris Pharma was founded in 2023 by Lyora Aharonov (Co-founder & CEO).
What sector is Emris Pharma in?
Emris Pharma operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is Emris Pharma located?
Emris Pharma is based in Wadi el-Haj St 13, Nazareth, Israel.